Mimedx (MDXG) Cost of Revenue (2011 - 2026)

Mimedx's Cost of Revenue history runs 16 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 4.89% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $73.8 million (up 15.99% YoY), while the FY2025 annual figure was $73.0 million, up 21.54% from the prior year.
• Cost of Revenue came in at $17.4 million for Q1 2026 at Mimedx, down from $19.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $19.1 million in Q4 2025 to a low of $9.9 million in Q1 2022.
• A 5-year average of $14.9 million and a median of $14.8 million in 2023 frame the typical range for Cost of Revenue.
• On a YoY basis, Cost of Revenue climbed as much as 102.44% in 2022 and fell as far as 7.34% in 2022.
• Mimedx's Cost of Revenue stood at $14.4 million in 2022, then slipped by 3.67% to $13.8 million in 2023, then gained by 22.16% to $16.9 million in 2024, then grew by 12.69% to $19.1 million in 2025, then dropped by 8.85% to $17.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $17.4 million, $19.1 million, and $18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison